Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Definitions
2.3. Biomarker Measurements
2.4. DNA Sequencing and TTN Mutation Analysis
2.5. Statistical Analysis
3. Results
3.1. Molecular Findings in the Study Cohort
3.2. Clinical Characteristics of the Study Population
3.3. Penetrance of Cardiotitinopathy Indicators
3.4. Results of Screening in Carriers of Cardiotitinopathy-Causing Truncating Variants
3.5. Outcome and Risk Stratification in Cardiotitinopathy
4. Discussion
4.1. Penetrance of Cardiotitinopathy Indicators
4.2. Risk Stratification including Biomarkers
4.3. Molecular Findings in the Study Cohort
4.4. Study Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hershberger, R.E.; Morales, A. Dilated Cardiomyopathy Overview. In GeneReviews(R); Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
- Herman, D.S.; Lam, L.; Taylor, M.R.; Wang, L.; Teekakirikul, P.; Christodoulou, D.; Conner, L.; DePalma, S.R.; McDonough, B.; Sparks, E.; et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 2012, 366, 619–628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Franaszczyk, M.; Chmielewski, P.; Truszkowska, G.; Stawinski, P.; Michalak, E.; Rydzanicz, M.; Sobieszczanska-Malek, M.; Pollak, A.; Szczygiel, J.; Kosinska, J.; et al. Titin Truncating Variants in Dilated Cardiomyopathy - Prevalence and Genotype-Phenotype Correlations. PLoS ONE 2017, 12, e0169007. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ware, J.S.; Li, J.; Mazaika, E.; Yasso, C.M.; DeSouza, T.; Cappola, T.P.; Tsai, E.J.; Hilfiker-Kleiner, D.; Kamiya, C.A.; Mazzarotto, F.; et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N. Engl. J. Med. 2016, 374, 233–241. [Google Scholar] [CrossRef] [PubMed]
- Tayal, U.; Newsome, S.; Buchan, R.; Whiffin, N.; Halliday, B.; Lota, A.; Roberts, A.; Baksi, A.J.; Voges, I.; Midwinter, W.; et al. Phenotype and Clinical Outcomes of Titin Cardiomyopathy. J. Am. Coll. Cardiol. 2017, 70, 2264–2274. [Google Scholar] [CrossRef] [PubMed]
- Roberts, A.M.; Ware, J.S.; Herman, D.S.; Schafer, S.; Baksi, J.; Bick, A.G.; Buchan, R.J.; Walsh, R.; John, S.; Wilkinson, S.; et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci. Transl. Med. 2015, 7, 270ra276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jansweijer, J.A.; Nieuwhof, K.; Russo, F.; Hoorntje, E.T.; Jongbloed, J.D.; Lekanne Deprez, R.H.; Postma, A.V.; Bronk, M.; van Rijsingen, I.A.; de Haij, S.; et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur. J. Heart Fail. 2017, 19, 512–521. [Google Scholar] [CrossRef] [PubMed]
- Haggerty, C.M.; Damrauer, S.M.; Levin, M.G.; Birtwell, D.; Carey, D.J.; Golden, A.M.; Hartzel, D.N.; Hu, Y.; Judy, R.; Kelly, M.A.; et al. Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. Circulation 2019, 140, 42–54. [Google Scholar] [CrossRef]
- Kryczka, K.E.; Dzielińska, Z.; Franaszczyk, M.; Wojtkowska, I.; Henzel, J.; Śpiewak, M.; Stępińska, J.; Bilińska, Z.T.; Płoski, R.; Demkow, M. Severe Course of Peripartum Cardiomyopathy and Subsequent Recovery in a Patient with a Novel TTN Gene-Truncating Mutation. Am. J. Case Rep. 2018, 19, 820–824. [Google Scholar] [CrossRef]
- Ware, J.S.; Amor-Salamanca, A.; Tayal, U.; Govind, R.; Serrano, I.; Salazar-Mendiguchia, J.; Garcia-Pinilla, J.M.; Pascual-Figal, D.A.; Nunez, J.; Guzzo-Merello, G.; et al. Genetic Etiology for Alcohol-Induced Cardiac Toxicity. J. Am. Coll. Cardiol. 2018, 71, 2293–2302. [Google Scholar] [CrossRef]
- Garcia-Pavia, P.; Kim, Y.; Restrepo-Cordoba, M.A.; Lunde, I.G.; Wakimoto, H.; Smith, A.M.; Toepfer, C.N.; Getz, K.; Gorham, J.; Patel, P.; et al. Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy. Circulation 2019, 140, 31–41. [Google Scholar] [CrossRef]
- Felkin, L.E.; Walsh, R.; Ware, J.S.; Yacoub, M.H.; Birks, E.J.; Barton, P.J.; Cook, S.A. Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation. JAMA Cardiol. 2016, 1, 234–235. [Google Scholar] [CrossRef] [Green Version]
- Valverde-Gomez, M.; Salguero-Bodes, R.; Martin-Arriscado, C.; Delgado-Jimenez, J.; Arribas-Ynsaurriaga, F.; Palomino-Doza, J. Truncating titin variants in dilated cardiomyopathy: Not only LVEF recovery, but also maintenance. Rev. Esp. Cardiol. 2020, 73, 589–592. [Google Scholar] [CrossRef]
- Tayal, U.; Newsome, S.; Buchan, R.; Whiffin, N.; Walsh, R.; Barton, P.J.; Ware, J.S.; Cook, S.A.; Prasad, S.K. Truncating Variants in Titin Independently Predict Early Arrhythmias in Patients With Dilated Cardiomyopathy. J. Am. Coll. Cardiol. 2017, 69, 2466–2468. [Google Scholar] [CrossRef]
- Corden, B.; Jarman, J.; Whiffin, N.; Tayal, U.; Buchan, R.; Sehmi, J.; Harper, A.; Midwinter, W.; Lascelles, K.; Markides, V.; et al. Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted Defibrillators. JAMA Netw. Open 2019, 2, e196520. [Google Scholar] [CrossRef] [Green Version]
- Akhtar, M.M.; Lorenzini, M.; Cicerchia, M.; Ochoa, J.P.; Hey, T.M.; Sabater Molina, M.; Restrepo-Cordoba, M.A.; Dal Ferro, M.; Stolfo, D.; Johnson, R.; et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ. Heart Fail. 2020, 13, e006832. [Google Scholar] [CrossRef]
- Chmielewski, P.; Michalak, E.; Kowalik, I.; Franaszczyk, M.; Sobieszczanska-Malek, M.; Truszkowska, G.; Stepien-Wojno, M.; Biernacka, E.K.; Foss-Nieradko, B.; Lewandowski, M.; et al. Can Circulating Cardiac Biomarkers Be Helpful in the Assessment of LMNA Mutation Carriers? J. Clin. Med. 2020, 9, 1443. [Google Scholar] [CrossRef]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef]
- Pinto, Y.M.; Elliott, P.M.; Arbustini, E.; Adler, Y.; Anastasakis, A.; Böhm, M.; Duboc, D.; Gimeno, J.; de Groote, P.; Imazio, M.; et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. Eur. Heart J. 2016, 37, 1850–1858. [Google Scholar] [CrossRef] [Green Version]
- Ploski, R.; Pollak, A.; Müller, S.; Franaszczyk, M.; Michalak, E.; Kosinska, J.; Stawinski, P.; Spiewak, M.; Seggewiss, H.; Bilinska, Z.T. Does p.Q247X in TRIM63 cause human hypertrophic cardiomyopathy? Circ. Res. 2014, 114, e2–e5. [Google Scholar] [CrossRef] [Green Version]
- Jordan, E.; Peterson, L.; Ai, T.; Asatryan, B.; Bronicki, L.; Brown, E.; Celeghin, R.; Edwards, M.; Fan, J.; Ingles, J.; et al. An Evidence-Based Assessment of Genes in Dilated Cardiomyopathy. Circulation 2021, 144, 7–19. [Google Scholar] [CrossRef]
- Tavtigian, S.V.; Greenblatt, M.S.; Harrison, S.M.; Nussbaum, R.L.; Prabhu, S.A.; Boucher, K.M.; Biesecker, L.G. Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet. Med. 2018, 20, 1054–1060. [Google Scholar] [CrossRef] [Green Version]
- Bilinska, Z.T.; Michalak, E.; Kusmierczyk-Droszcz, B.; Rydlewska-Sadowska, W.; Grzybowski, J.; Kupsc, W.; Ruzyllo, W. Left ventricular enlargement is common in relatives of patients with dilated cardiomyopathy. J. Card. Fail. 1995, 1, 347–353. [Google Scholar] [CrossRef]
- Michels, V.V.; Moll, P.P.; Miller, F.A.; Tajik, A.J.; Chu, J.S.; Driscoll, D.J.; Burnett, J.C.; Rodeheffer, R.J.; Chesebro, J.H.; Tazelaar, H.D. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N. Engl. J. Med. 1992, 326, 77–82. [Google Scholar] [CrossRef]
- Baig, M.K.; Goldman, J.H.; Caforio, A.L.; Coonar, A.S.; Keeling, P.J.; McKenna, W.J. Familial dilated cardiomyopathy: Cardiac abnormalities are common in asymptomatic relatives and may represent early disease. J. Am. Coll. Cardiol. 1998, 31, 195–201. [Google Scholar] [CrossRef] [Green Version]
- Schafer, S.; de Marvao, A.; Adami, E.; Fiedler, L.R.; Ng, B.; Khin, E.; Rackham, O.J.; van Heesch, S.; Pua, C.J.; Kui, M.; et al. Titin-truncating variants affect heart function in disease cohorts and the general population. Nat. Genet. 2017, 49, 46–53. [Google Scholar] [CrossRef] [Green Version]
- Huttner, I.G.; Wang, L.W.; Santiago, C.F.; Horvat, C.; Johnson, R.; Cheng, D.; von Frieling-Salewsky, M.; Hillcoat, K.; Bemand, T.J.; Trivedi, G.; et al. A-Band Titin Truncation in Zebrafish Causes Dilated Cardiomyopathy and Hemodynamic Stress Intolerance. Circ. Genom. Precis. Med. 2018, 11, e002135. [Google Scholar] [CrossRef] [Green Version]
- Pirruccello, J.P.; Bick, A.; Chaffin, M.; Aragam, K.G.; Choi, S.H.; Lubitz, S.A.; Ho, C.Y.; Ng, K.; Philippakis, A.; Ellinor, P.T.; et al. Titin Truncating Variants in Adults Without Known Congestive Heart Failure. J. Am. Coll. Cardiol. 2020, 75, 1239–1241. [Google Scholar] [CrossRef]
- McKie, P.M.; AbouEzzeddine, O.F.; Scott, C.G.; Mehta, R.; Rodeheffer, R.J.; Redfield, M.M.; Burnett, J.C., Jr.; Jaffe, A.S. High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. Clin. Chem. 2014, 60, 1225–1233. [Google Scholar] [CrossRef]
- Stege, N.M.; de Boer, R.A.; van den Berg, M.P.; Silljé, H.H.W. The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. Int. J. Mol. Sci. 2021, 22, 2955. [Google Scholar] [CrossRef]
- Suthahar, N.; Lau, E.S.; Blaha, M.J.; Paniagua, S.M.; Larson, M.G.; Psaty, B.M.; Benjamin, E.J.; Allison, M.A.; Bartz, T.M.; Januzzi, J.L., Jr.; et al. Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure. J. Am. Coll. Cardiol. 2020, 76, 1455–1465. [Google Scholar] [CrossRef]
- Grzybowski, J.; Bilinska, Z.T.; Janas, J.; Michalak, E.; Ruzyllo, W. Plasma concentrations of N-terminal atrial natriuretic peptide are raised in asymptomatic relatives of dilated cardiomyopathy patients with left ventricular enlargement. Heart 2002, 88, 191–192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vissing, C.R.; Rasmussen, T.B.; Dybro, A.M.; Olesen, M.S.; Pedersen, L.N.; Jensen, M.; Bundgaard, H.; Christensen, A.H. Dilated cardiomyopathy caused by truncating titin variants: Long-term outcomes, arrhythmias, response to treatment and sex differences. J. Med. Genet. 2020, 58, 832–841. [Google Scholar] [CrossRef] [PubMed]
- Arbustini, E.; Pilotto, A.; Repetto, A.; Grasso, M.; Negri, A.; Diegoli, M.; Campana, C.; Scelsi, L.; Baldini, E.; Gavazzi, A.; et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: A lamin A/C defect-related disease. J. Am. Coll. Cardiol. 2002, 39, 981–990. [Google Scholar] [CrossRef] [Green Version]
- Nakajima, K.; Aiba, T.; Makiyama, T.; Nishiuchi, S.; Ohno, S.; Kato, K.; Yamamoto, Y.; Doi, T.; Shizuta, S.; Onoue, K.; et al. Clinical Manifestations and Long-Term Mortality in Lamin A/C Mutation Carriers From a Japanese Multicenter Registry. Circ. J. 2018, 82, 2707–2714. [Google Scholar] [CrossRef] [Green Version]
- Kumar, S.; Baldinger, S.H.; Gandjbakhch, E.; Maury, P.; Sellal, J.M.; Androulakis, A.F.; Waintraub, X.; Charron, P.; Rollin, A.; Richard, P.; et al. Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. J. Am. Coll. Cardiol. 2016, 68, 2299–2307. [Google Scholar] [CrossRef]
- Saj, M.; Dabrowski, R.; Labib, S.; Jankowska, A.; Szperl, M.; Broda, G.; Szwed, H.; Tesson, F.; Bilinska, Z.T.; Ploski, R. Variants of the lamin A/C (LMNA) gene in non-valvular atrial fibrillation patients: A possible pathogenic role of the Thr528Met mutation. Mol. Diagn. Ther. 2012, 16, 99–107. [Google Scholar] [CrossRef]
- Choi, S.H.; Weng, L.C.; Roselli, C.; Lin, H.; Haggerty, C.M.; Shoemaker, M.B.; Barnard, J.; Arking, D.E.; Chasman, D.I.; Albert, C.M.; et al. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. Jama 2018, 320, 2354–2364. [Google Scholar] [CrossRef]
- Aimo, A.; Januzzi, J.L., Jr.; Vergaro, G.; Ripoli, A.; Latini, R.; Masson, S.; Magnoli, M.; Anand, I.S.; Cohn, J.N.; Tavazzi, L.; et al. Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. Circulation 2018, 137, 286–297. [Google Scholar] [CrossRef]
- Rapezzi, C.; Arbustini, E.; Caforio, A.L.; Charron, P.; Gimeno-Blanes, J.; Helio, T.; Linhart, A.; Mogensen, J.; Pinto, Y.; Ristic, A.; et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013, 34, 1448–1458. [Google Scholar] [CrossRef] [Green Version]
- Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016, 37, 2129–2200. [Google Scholar]
- Ozmen, C.; Deniz, A.; Deveci, O.S.; Cagliyan, C.E.; Celik, A.I.; Yildiz, I.; Yildiz, P.O.; Demir, M.; Kanadasi, M. Association among tenascin-C and NT-proBNP levels and arrhythmia prevalence in heart failure. Clin. Investig. Med. 2017, 40, E219–E227. [Google Scholar] [CrossRef] [Green Version]
- Medina, A.; Moss, A.J.; McNitt, S.; Zareba, W.; Wang, P.J.; Goldenberg, I. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. Heart Rhythm 2016, 13, 852–859. [Google Scholar] [CrossRef]
- Patton, K.K.; Sotoodehnia, N.; DeFilippi, C.; Siscovick, D.S.; Gottdiener, J.S.; Kronmal, R.A. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: The Cardiovascular Health Study. Heart Rhythm 2011, 8, 228–233. [Google Scholar] [CrossRef] [Green Version]
- Doisne, N.; Waldmann, V.; Redheuil, A.; Waintraub, X.; Fressart, V.; Ader, F.; Fossé, L.; Hidden-Lucet, F.; Gandjbakhch, E.; Neyroud, N. A novel gain-of-function mutation in SCN5A responsible for multifocal ectopic Purkinje-related premature contractions. Hum. Mutat. 2020, 41, 850–859. [Google Scholar] [CrossRef]
- Zakrzewska-Koperska, J.; Bilińska, Z.T.; Truszkowska, G.T.; Franaszczyk, M.; Elikowski, W.; Warmiński, G.; Kalin, K.; Urbanek, P.; Bodalski, R.; Orczykowski, M.; et al. A combination of quinidine/mexiletine reduces arrhythmia in dilated cardiomyopathy in two patients with R814W SCN5A mutation. ESC Heart Fail 2020, 7, 4326–4335. [Google Scholar] [CrossRef]
- Verdonschot, J.A.J.; Hazebroek, M.R.; Derks, K.W.J.; Barandiaran Aizpurua, A.; Merken, J.J.; Wang, P.; Bierau, J.; van den Wijngaard, A.; Schalla, S.M.; Abdul Hamid, M.A.; et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. Eur. Heart J. 2018, 39, 864–873. [Google Scholar] [CrossRef] [Green Version]
- Giudicessi, J.R.; Shrivastava, S.; Ackerman, M.J.; Pereira, N.L. Clinical Impact of Secondary Risk Factors in TTN-Mediated Dilated Cardiomyopathy. Circ. Genom. Precis. Med. 2021, 14, e003240. [Google Scholar] [CrossRef]
- Bondue, A.; Arbustini, E.; Bianco, A.; Ciccarelli, M.; Dawson, D.; De Rosa, M.; Hamdani, N.; Hilfiker-Kleiner, D.; Meder, B.; Leite-Moreira, A.F.; et al. Complex roads from genotype to phenotype in dilated cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovasc. Res. 2018, 114, 1287–1303. [Google Scholar] [CrossRef] [Green Version]
- Akhtar, M.; Elliott, P.M. Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. Curr. Cardiol. Rep. 2019, 21, 155. [Google Scholar] [CrossRef] [Green Version]
All Carriers N = 108 | DCM N = 70 (64.8%) | non-DCM N = 38 (35.2%) | p | |
---|---|---|---|---|
Age, years | 39.7 ± 15.5 | 40.5 ± 14.6 | 38.3 ± 17.2 | 0.475 |
Men | 67 (62.0%) | 55 (78.6%) | 12 (31.6%) | <0.001 |
Probands | 43 (39.8%) | 43 (61.4%) | 0 | <0.001 |
Symptoms | ||||
Heart failure | 54 (50.0%) | 54 (77.1%) | 0 | <0.001 |
NYHA class ≥3 | 14 (13.0%) | 14 (20.0%) | 0 | 0.002 |
Family history of SCD <50 years | 28 (25.7%) | 15 (21.4%) | 13 (34.2%) | 0.148 |
Arrhythmias and CCD | ||||
Atrial arrhythmias | 25 (23.1%) | 22 (31.4%) | 3 (7.9%) | 0.006 |
nsVT (n = 106) | 42 (39.6%) | 38 (55.1%) | 4 (10.8%) | <0.001 |
LBBB | 11 (10.2%) | 11 (15.7%) | 0 | 0.007 |
AV block (≥1st degree) | 15 (13.9%) | 13 (18.6%) | 2 (5.3%) | 0.056 |
Echocardiography | ||||
LVEF < 50% | 66 (61.1%) | 62 (88.6%) | 4 (10.5%) | <0.001 |
LVEF, % | 43.5 ± 13.8 | 36.2 ± 11.0 | 56.9 ± 6.6 | <0.001 |
LVEDD, mm | 58.3 ± 9.6 | 63.2 ± 8.0 | 49.4 ± 4.8 | <0.001 |
LAs, mm (n = 103) | 40.6 ± 8.1 | 43.7 ± 8.0 | 35.3 ± 4.9 | <0.001 |
Biomarkers in stable phase | ||||
hs-cTnT, ng/L (n = 90) | 4.4 [<3.0; 8.3] | 6.7 [3.8; 9.3] | <3.0 [<3.0; 4.2] | <0.001 |
hs-cTnT > 14 ng/L | 9 (10.0%) | 7 (12.5%) | 2 (5.9%) | 0.474 |
NT-proBNP, pg/mL (n = 72) | 244 [76; 1225] | 534 [157; 1498] | 72 [23; 94] | <0.001 |
NT-proBNP > 125 pg/mL | 47 (65.3%) | 46 (79.3%) | 1 (7.1%) | <0.001 |
NT-proBNP > 650 pg/mL | 24 (33.3%) | 24 (41.4%) | 0 | 0.003 |
Implantable devices | ||||
PM for bradyarrhythmias | 5 (4.6%) | 5 (7.1%) | 0 | 0.159 |
CRT-D | 2 (1.8%) | 2 (2.9%) | 0 | 0.540 |
ICD/CRT-D | 14 (13.0%) | 14 (20.0%) | 0 | 0.002 |
Events during Follow-Up | Total N = 108 | Men N = 67 (62.0%) | Women N = 41 (38.0%) | p |
---|---|---|---|---|
ICD in secondary prophylaxis | 2 (1.9%) | 1 (1.5%) | 1 (2.4%) | 1.00 |
CRT-D | 7 (6.5%) | 6 (9.0%) | 1 (2.4%) | 0.249 |
ICD/CRT-D implantation | 27 (25.0%) | 21 (31.3%) | 6 (14.6%) | 0.052 |
Malignant ventricular arrhythmia, n = 107 | 13 (12.1%) | 9 (13.4%) | 4 (10.0%) | 0.763 |
Appropriate ICD intervention, n = 27 | 13 (48.1%) | 9 (42.9%) | 4 (66.7%) | 0.384 |
Cardiopulmonary resuscitation, n = 106 | 2 (1.9%) | 2 (3.0%) | 0 | 0.530 |
Sudden cardiac death, n =106 | 1 (0.9%) | 0 | 1 (2.6%) | 0.368 |
End-stage heart failure, n = 107 | 13 (12.1%) | 12 (17.9%) | 1 (2.5%) | 0.024 |
LVAD | 5 (4.6%) | 5 (7.3%) | 0 | 0.155 |
Heart transplantation | 8 (7.4%) | 8 (11.9%) | 0 | 0.024 |
HF death, n = 106 | 5 (4.6%) | 4 (3.7%) | 1 (2.6%) | 0.650 |
Death | 9 (8.3%) | 6 (9.0%) | 3 (7.3%) | 1.00 |
Cumulate Incidence | p-Value Log-Rank | Univariable | Multivariable | |||
---|---|---|---|---|---|---|
HR [95% CI] | p-Value Wald | HR [95% CI] | p-Value Wald | |||
MVA + esHF | at 6 Years of Follow-Up | |||||
Sex: male vs. female | 32 vs. 14 | 0.033 | 3.08 [1.04; 9.18] | 0.043 | ||
AA: yes vs. no | 50 vs. 18 | 0.001 | 3.77 [1.56; 8.90] | 0.002 | ||
nsVT: yes vs. no | 46 vs. 7 | <0.001 | 5.5 [1.9; 16.5] | 0.002 | ||
LAs: ≥45 vs. <45 mm | 67 vs. 5 | <0.001 | 28.9 [6.7; 124.8] | <0.001 | ||
LVEF: <30 vs. ≥30% | 78 vs. 9 | <0.001 | 14.0 [5.5; 35.7] | <0.001 | ||
LBBB: yes vs. no | 86 vs. 16 | <0.001 | 8.5 [3.6; 20.4] | <0.001 | ||
NT-proBNP ≥650 vs. <650 pg/mL | 68 vs. 8 | <0.001 | 14.4 [3.6; 57.5] | <0.001 | 31.3 [4.0; 246] # | 0.001 # |
hs-cTnT: ≥18 vs. <18 ng/L | 75 vs. 13 | <0.001 | 7.7 [2.1; 28.6] | 0.002 |
Cumulate Incidence | p-Value Log-Rank | Univariable | Multivariable | |||
---|---|---|---|---|---|---|
HR [95% CI] | p-Value Wald | HR [95% CI] | p-Value Wald | |||
MVA | at 6 Years of Follow-Up | |||||
Sex: Male vs. Female | 21 vs. 14 | 0.362 | 1.72 [0.52; 5.59] | 0.368 | ||
SCD <50 in family: yes vs. no | 13 vs. 20 | 0.684 | 0.76 [0.21; 2.78] | 0.685 | ||
AA: yes vs. no | 35 vs. 14 | 0.010 | 3.81 [1.28; 11.36] | 0.016 | ||
nsVT: yes vs. no * | 39 vs. 2 | <0.001 | 12.5 [2.2; 72.7] | 0.005 | ||
LAs: ≥45 vs. <45 mm | 52 vs. 5 | <0.001 | 16.9 [3.7; 77.4] | <0.001 | ||
LVEF: <30% vs. ≥30% | 65 vs. 8 | <0.001 | 9.9 [3.2; 30.2] | <0.001 | ||
LBBB: yes vs. no * | 83 vs. 10 | <0.001 | 14.6 [4.8; 44.3] | <0.001 | ||
NT-proBNP ≥650 vs. <650 pg/mL | 59 vs. 8 | <0.001 | 12.7 [2.8; 58.3] | 0.001 | 11.7 [2.4; 56.6] # | 0.002 # |
hs-cTnT: ≥14 vs. <14 ng/L | 25 vs. 13 | 0.808 | 1.29 [0.16; 10.3] | 0.808 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chmielewski, P.; Truszkowska, G.; Kowalik, I.; Rydzanicz, M.; Michalak, E.; Sobieszczańska-Małek, M.; Franaszczyk, M.; Stawiński, P.; Stępień-Wojno, M.; Oręziak, A.; et al. Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment. Diagnostics 2022, 12, 13. https://doi.org/10.3390/diagnostics12010013
Chmielewski P, Truszkowska G, Kowalik I, Rydzanicz M, Michalak E, Sobieszczańska-Małek M, Franaszczyk M, Stawiński P, Stępień-Wojno M, Oręziak A, et al. Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment. Diagnostics. 2022; 12(1):13. https://doi.org/10.3390/diagnostics12010013
Chicago/Turabian StyleChmielewski, Przemysław, Grażyna Truszkowska, Ilona Kowalik, Małgorzata Rydzanicz, Ewa Michalak, Małgorzata Sobieszczańska-Małek, Maria Franaszczyk, Piotr Stawiński, Małgorzata Stępień-Wojno, Artur Oręziak, and et al. 2022. "Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment" Diagnostics 12, no. 1: 13. https://doi.org/10.3390/diagnostics12010013
APA StyleChmielewski, P., Truszkowska, G., Kowalik, I., Rydzanicz, M., Michalak, E., Sobieszczańska-Małek, M., Franaszczyk, M., Stawiński, P., Stępień-Wojno, M., Oręziak, A., Lewandowski, M., Leszek, P., Bilińska, M., Zieliński, T., Płoski, R., & Bilińska, Z. T. (2022). Titin-Related Dilated Cardiomyopathy: The Clinical Trajectory and the Role of Circulating Biomarkers in the Clinical Assessment. Diagnostics, 12(1), 13. https://doi.org/10.3390/diagnostics12010013